Overall impact
B (71)

Commentary

TELA Bio is a strong overall performer. With a 'B' rating of 70.6 for overall impact (83rd percentile compared to all companies), TELA Bio ranks 26th out of 103 industry peers, behind MyMD Pharmaceuticals, Alphatec, electroCore and 22 others, and ahead of Waters, Biolase, Biomerica and 74 others. On top material causes for TELA Bio's industry (Healthcare Equipment), TELA Bio performs well in Access to Affordable Healthcare (84.2 score), Conflict Free Mineral Production (96.0), Humane Treatment of Animals (80.7) and 4 other causes where it received an 'A' score and performs poorly in Reduced Green House Gas Emissions (33.6 score).
Impact
Cause TELA
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
209
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Supplies
SASB industry
Medical Equipment & Supplies
Headquarters
Pa, United States
Share classes
TELA
Description
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Material causes
Ethos considers the following causes material for TELA Bio, based on its industry sub-industry Health Care Supplies. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.